Cartalax peptide is a Russian-developed research peptide studied for cartilage and joint tissue. Learn how it's sold, what studies show, and safety concerns.
Cartalax peptide is a short synthetic peptide bioregulator developed in Russia and studied mainly for its effects on cartilage and bone tissue. It is not FDA-approved for human use, and in the United States it is sold almost exclusively as a research chemical rather than a medicine. Claims that Cartalax peptide treats arthritis or rebuilds joints go well beyond what published human data currently support.
What Is Cartalax Peptide?
Cartalax is one of a family of short peptides — often called peptide bioregulators — created by researchers at the St. Petersburg Institute of Bioregulation and Gerontology. It is commonly described as the tetrapeptide Ala-Glu-Asp-Pro (AEDP), built from four amino acids: alanine, glutamic acid, aspartic acid, and proline. The name is sometimes transliterated as Kartalaks.
The idea behind this class of compounds is that very short amino acid chains can mimic signals that specific tissues use to regulate repair and gene expression. Cartalax is the member of the family associated with cartilage, connective tissue, and bone.
- Class: Synthetic short peptide (peptide bioregulator)
- Commonly cited sequence: Ala-Glu-Asp-Pro (AEDP)
- Origin: Russian peptide research, 1980s–2000s
- Studied for: Cartilage, joints, bone, and connective tissue
- US regulatory status: Not approved for human use; sold for research only
What Cartalax Peptide Is Studied For
Most of the literature on Cartalax comes from Russian-language animal and in-vitro studies. The recurring themes are cartilage regeneration, bone density, and tissue repair after injury.
- Cartilage tissue repair and chondrocyte function
- Bone remodeling and osteochondrosis models
- Connective tissue maintenance with age
- Joint comfort in animal models of induced arthritis
It is worth separating these laboratory findings from real-world expectations. Animal and cell studies are a starting point, not proof. Cartalax peptide has not been through randomized, placebo-controlled human trials of the kind required for FDA approval, and no such results have been published in major English-language medical journals.
Researchers comparing compounds in this space frequently mention bpc-157 peptide for inflammation alongside Cartalax, although the two are studied for different tissues and with very different evidence bases.
Cartalax Compared With Other Research Peptides
The research peptide market is crowded, and Cartalax is far less known than compounds like BPC-157 or TB-500. The table below puts the most commonly discussed options side by side.
| Peptide | Primary research focus | Typical research form | US regulatory status |
|---|---|---|---|
| Cartalax | Cartilage, bone, connective tissue | Lyophilized powder | Not approved; research use only |
| BPC-157 | Gut lining, tendon and soft-tissue repair, inflammation | Lyophilized powder, capsules | Not approved; research use only |
| TB-500 | Actin regulation, wound healing, flexibility | Lyophilized powder | Not approved; research use only |
| Bremelanotide (PT-141) | Sexual desire signaling | Prescription injection | FDA-approved for one specific indication |
| Collagen peptides | Dietary protein supplement | Powder, capsules, drinks | Legal food supplement |
That comparison highlights the key distinction: bremelanotide went through formal clinical development and became a prescription drug, while Cartalax has not. That is a difference in evidence, not just in marketing.
It also helps to know where consumer products fit. Someone looking for a peptide for skin is browsing cosmetic formulations, not a cartilage research compound. In the same way, collagen peptide supplements are digested proteins sold as nutrition, not signaling molecules tested in cell culture.
Forms, Dosing, and Administration
Cartalax is usually sold as a lyophilized (freeze-dried) powder in a small vial, and buyers typically reconstitute it with bacteriostatic water. Some vendors also offer capsules or a topical cream, although absorption data for those formats is essentially absent.
There is no established human dosage for Cartalax peptide. Published animal work uses varied concentrations, and none of it translates directly into a safe human dose. Anyone considering a peptide injection should understand that self-dosing an unapproved substance carries real risk, including infection, allergic reaction, and contamination from poorly manufactured product.
There is no FDA-approved dose of Cartalax peptide, and no manufacturer has published human pharmacokinetic data for it.
Safety, Legality, and Quality Concerns
In the US, Cartalax is not a legal dietary supplement ingredient and is not an approved drug. Vendors stay within the law by labeling it "for research use only — not for human consumption."
- Purity: Independent testing has repeatedly found underdosed or mislabeled peptides from online sellers.
- Sterility: Powders intended for laboratory use are not manufactured to injectable standards.
- Unknown long-term effects: Cartalax has decades of animal research but no long-term human safety record.
- Sport and employment rules: Peptide use can violate anti-doping codes and some workplace policies.
People with joint pain have legitimate, evidence-based options, including physical therapy, anti-inflammatory medication, and physician-guided injections. A doctor is also the right person to ask about interactions with medications you already take. Peptide drug development is a slow, regulated process, and the compounds that succeed in it look very different from a vial sold online with no batch documentation.
What to Look For in a Research Peptide Supplier
- A certificate of analysis from a third-party lab, not an in-house PDF
- HPLC and mass spectrometry results with batch numbers that match the vial
- Clear "not for human consumption" labeling, which signals honesty about legal status
- No disease treatment claims, which would be illegal for an unapproved substance
- Transparent shipping and storage instructions, since peptides degrade with heat
Even a compliant supplier only confirms that the powder matches its label. It does not confirm that Cartalax peptide is safe or effective in people.
Bottom Line
Cartalax peptide is a Russian-developed research peptide associated with cartilage and bone tissue, backed mainly by animal and laboratory data. It is not FDA-approved, has no established human dose, and is sold legally in the US only for research purposes.
If you have joint or cartilage problems, talk with a healthcare professional about treatments that have real clinical evidence behind them. Cartalax peptide remains an open research question, not a proven therapy.
Frequently Asked Questions
What is Cartalax peptide used for?
Cartalax peptide is studied for cartilage, bone, and connective tissue effects in animal and laboratory research. In practice, it is sold as a research chemical, not as a treatment for arthritis or any other human condition. There is no approved human use for it in the United States.
Is Cartalax peptide FDA-approved?
No. Cartalax peptide is not FDA-approved for any human use in the United States. It cannot legally be sold as a dietary supplement or a prescription drug, so vendors label it for research use only. Any product marketed as a treatment for joint disease is being sold illegally.
What is the typical Cartalax peptide dosage?
There is no established human dosage for Cartalax peptide. Animal studies use varying amounts that do not translate into a safe human dose. Anyone considering it should speak with a healthcare professional first, since self-dosing unapproved peptides carries infection, allergy, and contamination risks.
This page provides educational research information and does not replace medical advice, diagnosis, or treatment.